The NUP214-ABL1 fusion kinase has recently been identified in 6% of patients with T-cell acute lymphoblastic leukemia. In contrast to the more common oncogenic ABL1 fusion BCR-ABL1, NUP214-ABL1 localizes to the nuclear pore complexes and has attenuated transforming properties in hematopoietic cells and in mouse bone marrow transplant models. We have performed a thorough biochemical comparative analysis of NUP214-ABL1 and BCR-ABL1 and show that, despite their common tyrosine kinase domain, the two fusion proteins differ in many critical catalytic properties. NUP214-ABL1 has lower in vitro tyrosine kinase activity, which is in agreement with the absence of phosphorylation on its activation loop. NUP214-ABL1 was more sensitive to imatinib (Glivec) than BCR-ABL1 in vitro and in cells, indicating a different activation state and conformation of the two ABL1 fusion kinases. Using a peptide array, we identified differences in the spectrum and efficiency of substrate peptide phosphorylation and a differential involvement of Src kinases in downstream signaling. These results clearly indicate that different fusion partners of the same kinase can determine not only localization, but also critical functional properties of the enzyme such as inhibitor sensitivity and substrate preference, with subsequent differences in downstream signaling effectors and likely consequences in disease pathogenesis.
Introduction
Deregulated activity of tyrosine kinases has been identified in various human tumors. 1, 2 Both receptor as well as nonreceptor tyrosine kinases are strictly regulated in normal cells and display only low activity in the absence of activating events, such as binding of growth factors or recruitment to activated receptors. During the last decades, several molecular mechanisms have been identified that lead to aberrant tyrosine kinase activation. Such mechanisms include point mutations in the tyrosine kinase domain, mutations, deletions or tandem duplications in autoinhibitory domains or the formation of fusion proteins that disrupt inhibitory interactions and/or lead to constitutive dimerization/oligomerization. [3] [4] [5] These aberrant kinase variants usually display constitutive tyrosine kinase activity, are able to transform growth factor-dependent cell lines to growth factor independence and are transforming/oncogenic in different cell culture and animal models. 6 The first chromosomal translocation identified, t(9;22) (q34;q11), leads to formation of the aberrant Philadelphia chromosome, on which the 5 0 part of the break point cluster region (BCR) gene is fused to the first intron of the nonreceptor tyrosine kinase encoding ABL1 gene. This results in the expression of the BCR-ABL1 fusion proteins with apparent molecular weights of either 185, 210 or 230 kDa, depending on the location of the break point in BCR. Expression of BCR-ABL1 is considered to be sufficient for the transformation of hematopoietic stem cells leading to the initiation and maintenance of chronic myeloid leukemia (CML). In addition, BCR-ABL1 is detected in 25% of adult B-cell acute lymphoblastic leukemia (ALL) patients. [7] [8] [9] [10] [11] The BCR-ABL1 kinase obtains its constitutive activity and its transforming capacity through a combination of oligomerization via the coiled-coiled domain comprised in the N-terminus of BCR, through loss of the autoinhibitory N-terminal myristoyl group and through binding of the adaptor protein GRB2 to phosphorylated Tyr-177 in BCR resulting in activation of RAS and PI3K signaling pathways. [12] [13] [14] [15] The central function of BCR-ABL1 in the pathophysiology of CML led to the development of the specific BCR-ABL1 inhibitor imatinib (Glivec), which is now the frontline therapy for CML in all disease stages, 16 and the more potent inhibitors nilotinib (Tasigna) and dasatinib (Sprycel), which show activity against several imatinib-resistant BCR-ABL1 point mutants. 17, 18 Recently, fusions between the C-terminal part of the ABL1 kinase and different partners have been identified. These include TEL-ABL1, EML1-ABL1 and NUP214-ABL1 and cause different forms of myeloid and acute lymphocytic leukemias. [19] [20] [21] As for BCR-ABL1, TEL-ABL1 and EML1-ABL1 have been described to contain domains that cause oligomerization of the fusion kinases and were shown to be necessary for kinase activation and for cellular transformation properties by these fusion proteins. 19, 22 In addition, these three fusion proteins appear to phosphorylate a similar set of substrates and thereby activate similar signal transduction pathways such as BCR-ABL1. 23 In contrast, the NUP214-ABL1 fusion appears to differ in many aspects from other ABL1 fusion kinases. NUP214-ABL1 lacks oligomerization domains that are sufficient for ABL1 kinase activation or for generation of a transforming ABL1 fusion. Moreover, whereas all other ABL1 fusion kinases are localized to the cytoplasm or cortical actin cytoskeleton, NUP214-ABL1 is localized to the nuclear pore complex and is strictly dependent on this subcellular localization for its activity and oncogenic transformation. 24, 25 In addition, NUP214-ABL1 lacks a direct binding site for the adaptor protein GRB2 that was shown to contribute to transformation and leukemogenesis of BCR-ABL1  and TEL-ABL1 12,14,15,26 and lacks phosphorylation of its activation loop (Tyr-412). 24, 27 Finally, NUP214-ABL1 has attenuated transforming capacity as compared with BCR-ABL1 and preferentially transforms T cells, which is in agreement with its unique occurrence in T-cell ALL. 24 On the basis of these observations, we have performed a thorough comparison of NUP214-ABL1 and BCR-ABL1 to highlight the unique biochemical properties of NUP214-ABL1 and to gain mechanistic insight in the different disease phenotypes caused by these two oncoproteins. Besides absent activation loop phosphorylation, we show that NUP214-ABL1 displays much lower general tyrosine autophosphorylation, higher Michaelis-Menten constant (K M ) and lower relative maximum velocity (V max ) values than BCR-ABL1. Apart from enzymatic parameters, imatinib inhibits NUP214-ABL1 in vitro kinase activity and NUP214-ABL1-dependent cell proliferation more effectively than BCR-ABL1, suggesting differences in the conformation and activation state of the kinase domains of NUP214-ABL1 and BCR-ABL1. In contrast, both fusion kinases showed very similar sensitivity for dasatinib. Using arrays with immobilized tyrosine kinase substrate peptides, we show that NUP214-ABL1 displays differential substrate specificity compared with BCR-ABL1. Our data further underscore that NUP214-ABL1 differs in many aspects from the well-characterized BCR-ABL1 fusion kinase and illustrate that two fusion kinases sharing exactly the same kinase part can have very different biochemical properties depending on the kinase fusion partner.
Materials and methods

Cell lines
K562 and ALL-SIL cells were obtained from DSMZ (Braunschweig, Germany) and were cultured in RPMI-1640 medium supplemented with 20% fetal calf serum. HEK293 cells were grown in DMEM/F12 medium þ 10% fetal calf serum. Ba/F3 cells expressing BCR-ABL1 or NUP214-ABL1 were described previously 24 and were grown in RPMI-1640 þ 10% fetal calf serum.
Immunoblotting
Samples were analyzed by standard procedures using the following antibodies: anti-ABL1 (Ab-3, Oncogene Science, Cambridge, MA, USA), anti-phospho-tyrosine (4G10, Millipore, Billerica, MA, USA), anti-phospho-ABL1 (Tyr-245), anti-phospho-ABL1 (Tyr-412) and anti-phospho-Src (Rous Sarcoma virus oncogene homolog) family (Tyr-416) (Cell Signaling, Beverly, MA, USA), anti-Lyn(44) (Santa Cruz, Santa Cruz, CA, USA) and AlexaFluor 688-labeled goat anti-mouse IgG (Molecular Probes, Eugene, OR, USA) or peroxidase-labeled anti-mouse/anti-rabbit antibodies (AP Biotech, Uppsala, Sweden). Band intensities were quantified using the Li-cor Odyssey system.
Kinase inhibitors
Dasatinib (BMS-354825) and imatinib (STI-571) were synthesized by WuXi PharmaTech (Shanghai, China). Twenty-millimolar stock solutions of the kinase inhibitors were prepared in dimethylsulphoxide and diluted in kinase assay buffer or cell culture medium to the indicated final concentrations.
Kinase assays
Immunoprecipitation of ABL1 protein and ABL1 in vitro kinase assay was carried out as described previously. 13, 28 A peptide with the preferred ABL1 substrate sequence 29 carrying an N-terminal biotin (biotin-GGEAIYAAPFKK-amide) was used as substrate. The terminated reaction was spotted onto a SAM2 Biotin Capture membrane (Promega, Madison, WI, USA) and further treated according to the instructions of the manufacturer. The relative amount of immunoprecipitated ABL1 protein was determined by immunoblotting (anti-ABL1 Ab-3, Oncogene Science) and subsequently quantified using the Li-cor Odyssey system.
In vitro drug inhibition assay
Immunoprecipitated ABL1 proteins were resuspended in kinase assay buffer (for control reactions) or kinase assay buffer containing the indicated concentrations of dasatinib or imatinib. The kinase assay was carried out as described above. Each experiment was normalized for a reaction in the absence of kinase inhibitor, and relative ABL1 activity was calculated.
Cellular drug inhibition assay
For dose-response curves, 2 Â 10 5 Ba/F3 cells were seeded in 1 ml medium and incubated in the presence of imatinib or dasatinib for 24 h. Viable cell numbers were determined on a Vi-cell XR cell viability analyzer (Beckman Coulter, Fullerton, CA, USA). Cell proliferation in the absence of inhibitor ( ¼ control) was set to 100%, the results represent the average ± s.e.m. of three determinations.
PamChip assay
Cells lysed in M-PER Mammalian Protein Extraction Reagent (Thermo Fisher Scientific, Waltham, MA, USA) containing Halt phosphatase and Halt protease inhibitor cocktails (Thermo Fisher Scientific) were snap-frozen until analysis on a PamChip96 (PamGene, 's-Hertogenbosch, The Netherlands). Thawed lysates were centrifuged for 10 min at 12 000 g and supernatants were filtered through a 0.2 mm filter (Anotop 0.2 mm anopore filter; GE Healthcare, Waukesha, WI, USA). Total protein content was quantitated and lysates were diluted to 1 mg/ml in M-PER buffer containing phosphatase and protease inhibitors. Ten mg of total lysate (corresponding to 10 ml) was used per well on the PamChip96. The lysate was then 1:1 diluted with imatinib or dimethylsulphoxide diluted to the appropriate concentration in 10 mM Tris-HCl, pH 7.5. Meanwhile, a PamChip96 tyrosine peptide chip was blocked with 2% bovine serum albumin (filtered through 0.2 mm filter) using the standard setting of a PamStation96 (PamGene). The composition of the kinase buffer was 1 Â ABL buffer (New England Biolabs, Ipswich, MA, USA), 0.5 mg/ml bovine serum albumin, 100 mM ATP and 5 mg/ml PY20-FITC (ExAlpha Biologicals, Maynard, MA, USA). A twofold concentrated kinase buffer containing appropriate dimethylsulphoxide or compound concentrations was added 1:1 to the (compound-treated) lysates followed by immediate application of the samples on a tyrosine peptide PamChip96. The assay was run on a PamStation96 according to standard procedures: after loading of the plate, solution was pumped once onto the wells, a first exposure was read (150 ms) and then a kinetic reading program (reading every 5 min for 150 ms) was run for 60 min. Lysates were run in four technical replicates for each condition and were applied horizontally next to each other to avoid vertical strip effects of the chip. The data (spot images) were quantified and linked to the peptide identities using Evolve PamGrid software (PamGene). Quantified data were then fitted to a curve using CurveFitHT software (PamGene) using the Vinip2 curve-fitting algorithm, applied on the first 30 min of the assay; the initial velocity (V ini ) is derived at the first kinetic time point read, and all subsequent data analyses were done on these V ini values. Replicates from visually damaged wells or with interreplicate correlation coefficients lower than 0.95 were removed from the analysis.
Results and discussion
NUP214-ABL1 and BCR-ABL1 differ an order of magnitude in their level of autophosphorylation
To study the enzymatic properties of ABL1 fusion kinases, we used the ALL-SIL T-cell ALL cell line expressing NUP214-ABL1 and the K562 CML cell line expressing BCR-ABL1. We used a monoclonal antibody recognizing an epitope in the C-terminal F-actin-binding domain of ABL1, which is present in NUP214-ABL1 and BCR-ABL1, to immunoprecipitate each of these proteins. As the antibody also immunoprecipitates endogenous ABL1 from both cell lines, we used lysates from HEK293 cells that do not express oncogenic ABL1 fusions as a control. Anti-ABL1 immunoprecipitates from different amounts of cell extract were immunoblotted with anti-Abl and anti-phosphotyrosine antibodies (Figure 1a) . We detected strong autophosphorylation of BCR-ABL1 in K562 cells, but only a very weak signal for NUP214-ABL1 autophosphorylation in ALL-SIL cells was observed at the highest extract concentration (Figure 1a) . Quantification of the normalized signals showed that NUP214-ABL1 displays only B10% of the phosphotyrosine signal obtained with BCR-ABL1 (Figure 1b) . In all three cell lines, no autophosphorylation of ABL1 could be detected.
Strong tyrosine phosphorylation of BCR-ABL1 can be explained by phosphorylation of more than 20 different tyrosine residues that have been mapped by mass spectrometry to date. 4, [30] [31] [32] The majority of these known tyrosine phosphorylation sites map to the ABL1 part of BCR-ABL1 and are thought to be autophosphorylation sites. As NUP214-ABL1 shares these sites with BCR-ABL1, our results can be explained either by differences in protein-protein interaction partners due to distinct subcellular localization or weaker activation of NUP214-ABL1 as compared with BCR-ABL1, which may, for instance, be caused by recruitment of a different set of phosphatases.
To corroborate this finding, we have used antibodies against the two best characterized ABL1 phosphorylation sites, Tyr-412 in the activation loop and Tyr-245 in the linker region between the SH2 domain and the kinase domain. 4, 33, 34 Whereas phosphorylation of Tyr-412 is required to stabilize the activation loop in an open conformation and is associated with high catalytic output, phosphorylation on Tyr-245 appears to stabilize an active kinase conformation by interfering with the autoinhibitory binding of the SH3 domain to the SH2-kinase domain linker. As previously published, although Tyr-245 is 24 also data not shown). To exclude that these differences are caused by the different expression of kinases or phosphatases in K562 and ALL-SIL that are responsible for regulating the steady-state levels of phosphorylation on Tyr-412 and Tyr-245, these experiments were also performed in Ba/F3 and HEK293 cells that expressed NUP214-ABL1 and BCR-ABL1. Also in Ba/F3 and HEK293 cells, no phosphorylation on Tyr-412 could be detected in NUP214-ABL1 (Figure 1c ; see De Keersmaecker;
24 also data not shown). These results indicated that both NUP214-ABL1 and BCR-ABL1 are constitutively active tyrosine kinases, but the differences in phosphorylation pattern argue that NUP214-ABL1 is a weaker kinase than BCR-ABL1.
NUP214-ABL1 has a higher K M and lower V max than BCR-ABL1 for an optimal ABL1 substrate peptide
We next determined the basic kinetic parameters of the two ABL1 fusion enzymes. To this end, we prepared ABL1 immunoprecipitates from ALL-SIL and K562 cells and performed in vitro immunocomplex kinase assays using an optimal ABL1 substrate peptide in increasing concentrations and at constant ATP concentration, well above the K M for ATP determined for BCR-ABL1 (OH, unpublished data). This enabled us to determine K M and V max for the two full-length kinases (Figure 2 ). NUP214-ABL1 displayed a higher K M value than BCR-ABL1, indicating lower affinity for the peptide substrate in NUP214-ABL1. The V max value for BCR-ABL1 was determined to be B2-fold higher than for NUP214-ABL1, suggesting a lower overall catalytic output at substrate concentration saturation of NUP214-ABL1. Overall, these experiments showed that NUP214-ABL1 is less active than BCR-ABL1.
NUP214-ABL1 is more sensitive to imatinib inhibition than BCR-ABL1
ABL1 kinase inhibitors, similar to imatinib, have revolutionized CML therapy during the recent years. 16 The safety and efficacy of imatinib can be explained by the ability of the drug to exclusively bind the ABL1 kinase domain in an inactive conformation in which the activation loop tyrosine (Tyr-412) is not phosphorylated. 35, 36 In contrast, binding of the secondgeneration ABL1 inhibitor dasatinib does not depend on the configuration of the ABL1 kinase activation loop. Initially, this inhibitor was thought to bind ABL1 both in its active and its inactive conformation, 37 but recent evidence from NMR experiments clearly showed an exclusive preference of dasatinib for the active ABL1 conformation. 38, 39 Therefore, imatinib and dasatinib can be used as conformation-specific probes targeting the inactive and active conformations of the ABL1 activation loop, respectively, and therefore distinct activation states of the ABL1 kinase. 13 As we had observed the striking differences in autophosphorylation and in vitro kinase activity of NUP214-ABL1 and BCR-ABL1, we next asked whether the two kinases would also differ in their sensitivity toward imatinib and dasatinib. We again prepared ABL1 immunoprecipitates from ALL-SIL and K562 cells, added various concentrations of imatinib or dasatinib to the kinase assay and measured phosphorylation of an ABL1 substrate peptide 29 , (Figure 3 ). For dasatinib, the in vitro inhibition curves for the two kinases showed an almost identical appearance with IC 50 values of B17 nM (Figure 3, left  panel) . In contrast, the in vitro inhibition curve obtained with imatinib showed a clear difference between NUP214-ABL1 and BCR-ABL1 (Figure 3, right panel) . We observed that NUP214-ABL1 is two-to threefold more sensitive to imatinib inhibition in vitro than BCR-ABL1. The relatively increased sensitivity of NUP214-ABL1 toward imatinib correlated with the absence of detectable phosphorylation on the residue corresponding to Tyr-412 in NUP214-ABL1 and with the 10-fold lower levels of NUP214-ABL1 autophosphorylation compared with BCR-ABL1.
NUP214-ABL1 and BCR-ABL1 phosphorylate a different spectrum of substrate proteins in vitro
To investigate whether NUP214-ABL1 and BCR-ABL1 display differences in their substrate specificity, we analyzed cell lysates derived from BCR-ABL1 and NUP214-ABL1 expressing Ba/F3 cells on the PamChip96 tyrosine peptide chip, a peptide array containing 144 peptides corresponding to tyrosine kinase substrates (Figure 4a ). Application of a cell lysate of NUP214-ABL1 transformed Ba/F3 cells resulted in phosphorylation of 92 out of 144 peptides spotted on the array (with a minimal initial Table 1 ). Not only did the BCR-ABL1 lysate induce phosphorylation of more peptides on the array, the average V ini of phosphorylation of the overlapping 91 peptides was also significantly higher for the BCR-ABL1 lysate (V ini,av ¼ 219) than for the NUP214-ABL1 lysate (V ini,av ¼ 135) (Figure 4a ). This is in line with the experiments presented above, indicating that NUP214-ABL1 is a weaker kinase than BCR-ABL1, but shows that the two kinases largely overlap in their substrate specificity. Interestingly, the 15 peptides that were specific for the BCR-ABL1 lysate prominently contained peptides from members of the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) signaling pathway (Jak1, STAT3 and STAT4) and mitogen-activated protein kinases (extracellular signal-regulated kinase-2, c-Jun N-terminal kinase-3, p38g and p38a).
To distinguish peptides specifically phosphorylated by BCR-ABL1 or NUP214-ABL1, the same experiments were also performed in the presence of imatinib. In total, the phosphorylation of 19 peptides was found to be inhibited by imatinib. The overlap of the peptides that were inhibited by imatinib for BCR-ABL1 and NUP214-ABL1 lysates comprised only 3 of the 19 inhibited peptides. For 10 out of the 106 peptides that were found to be phosphorylated by the BCR-ABL1 lysate, phosphorylation was inhibited by imatinib (Figure 4c , Supplementary Table 2 ). From these 10 phosphorylated peptides, 7 were inhibited for the BCR-ABL1 lysate and not or only weakly inhibited for the NUP214-ABL1 lysate, suggesting that these are specific substrates of BCR-ABL1 (Figures 4c and e , Supplementary Table 2 ). It is interesting to note again that, among the seven peptides specifically inhibited by imatinib in the BCR-ABL1 lysate, we prominently identified members of the JAK-STAT pathway and mitogen-activated protein kinases. Imatinib also inhibited phosphorylation of 12 out of 92 peptides phosphorylated by the NUP214-ABL1 lysate (9 out of 12 peptides were inhibited in the NUP214-ABL1 condition and not or only weakly inhibited in the BCR-ABL1 condition, whereas 3 out of 12 peptides were inhibited for the BCR-ABL1 and the NUP214-ABL1 lysate) (Figures 4c, d and f, Supplementary Table 2 ). Most interestingly, although NUP214-ABL1 and BCR-ABL1 largely were able to phosphorylate the same peptides, our experiments identified a few specific substrates for each of the two kinases and showed that some substrates are differentially inhibited by imatinib.
In summary, this set of experiments supports our general conclusion that NUP214-ABL1 is a weaker kinase and that NUP214-ABL1 and BCR-ABL1 have some unique substrates.
NUP214-ABL1 downstream signaling pathways are more sensitive to imatinib and dasatinib inhibition than those of BCR-ABL1
Having assessed the sensitivity of the NUP214-ABL1 and BCR-ABL1 kinases to imatinib in vitro, we compared inhibition of proliferation of BCR-ABL1-and NUP214-ABL1-transformed Ba/F3 cells by imatinib. In contrast to the in vitro kinase assays, where only the direct effect of imatinib and dasatinib on ABL1 kinase activity is assessed, inhibition of cell proliferation is mostly caused by inhibition of the ABL1 kinases themselves, but also by inhibition of additional cellular targets of imatinib and dasatinib, and of kinases in downstream signaling pathways. As in ALL-SIL cells, no phosphorylation on Tyr412 could be detected in Ba/F3 cells transformed with NUP214-ABL1 (De Keersmaecker   24 ). Proliferation of NUP214-ABL1-expressing Ba/F3 cells was inhibited at B55-fold lower imatinib concentrations than that of BCR-ABL1-transformed Ba/F3 cells (IC 50 values of 3 and 166 nM, respectively; Figure 5a ). This result is in line with the increased imatinib sensitivity of NUP214-ABL1 in vitro, although the effect in this cellular readout assay was much more pronounced. One likely explanation is that NUP214-ABL1 may get partially activated, and therefore phosphorylated on Tyr-412, upon immunoprecipitation resulting in smaller differences in imatinib sensitivity in vitro. In addition, the situation in cells is much more complex, as inhibition of cell proliferation is the result of blocking ABL1 kinase activity and consecutive abrogation of its downstream signaling pathways that may differ between and contribute to a different extent to NUP214-ABL1-and BCR-ABL1-dependent proliferation.
To study the effects of imatinib on downstream signaling pathways, we performed western blot analysis of BCR-ABL1-and NUP214-ABL1-expressing Ba/F3 cells treated with increasing imatinib concentrations. NUP214-ABL1 autophosphorylation on Tyr-245 was only slightly more sensitive to imatinib than that of BCR-ABL1 (Figure 5b , upper panels). In contrast, phosphorylation of Src family kinases, known downstream signaling molecules of oncogenic ABL1 fusions, 19, 40, 41 was inhibited at lower imatinib concentrations in NUP214-ABL1-expressing Ba/F3 cells than in BCR-ABL1 expressing Ba/F3 cells (Figure 5b , lower panels). As imatinib is not inhibiting Src kinases, the observed inhibition of Src phosphorylation must be indirectly caused, likely through inhibition of ABL1 as upstream activator of Src kinases in these cells. It is also intriguing that in BCR-ABL1-expressing Ba/F3 cells, Src phosphorylation remained detectable at imatinib concentrations, at which BCR-ABL1 autophosphorylation was fully inhibited and at which cells do not proliferate any more (Figure 5b ). In contrast, inhibition of Src phosphorylation in NUP214-ABL1 cells was more sensitive than inhibition of ABL1 autophosphorylation itself by imatinib, indicating a much stronger dependence of NUP214-ABL1 signaling on Src kinases, possibly explaining the exquisite sensitivity of NUP214-ABL1-expressing cells to imatinib.
It is now well established that dasatinib, in contrast to imatinib, is a very broad-specificity kinase inhibitor that potently inhibits all major nonreceptor tyrosine kinases, including the Src kinases and Btk/Tec, different receptor tyrosine kinases and many serine/threonine kinases. [42] [43] [44] When we assayed the proliferation of NUP214-ABL1-expressing Ba/F3 cells in the presence of dasatinib, proliferation was inhibited at two-to threefold lower dasatinib concentrations than that of BCR-ABL1-transformed Ba/F3 cells (Figure 5c ). This is a much smaller difference than the 55-fold difference in imatinib sensitivity that we observed between the two cell lines. As dasatinib is inhibiting Src kinases directly, ABL1 kinase-dependent signaling is doubly blocked. The higher dasatinib sensitivity of NUP214-ABL1-expressing cells again suggests a stronger dependence of NUP214-ABL1 signaling on the Src kinases.
Conclusions
NUP214-ABL1 and BCR-ABL1 are intriguing examples of two fusion oncoproteins that, despite carrying the same catalytic tyrosine kinase domain, differ in almost any biological property Biochemical comparison of BCR-ABL1 and NUP214-ABL1 K De Keersmaecker et al that we have been studying. NUP214-ABL1 has a different subcellular localization and a different molecular mechanism of activation and leads to a different form of leukemia in humans and mice as compared with BCR-ABL1. 24 Here, we have shown that the two ABL1 fusions also differ in their phosphorylation status, enzymatic activity, sensitivity to imatinib and dasatinib, substrate spectrum and activation of downstream signaling. It is now well established that isolated tyrosine kinase domains display sequence specificity toward their substrate on a peptide level and are also able to differentiate between tyrosine residues in a physiological substrate. [45] [46] [47] Therefore, the ABL1 kinase domain of NUP214-ABL1 and BCR-ABL1 would be expected to phosphorylate the same set of substrates. Furthermore, although the fusion partner is different, both proteins contain most of the protein-protein interaction domains of ABL1, including the SH3 and SH2 domain, proline-rich sequences for SH3 docking and phosphorylation sites. However, the fusion of ABL1 to either NUP214 or BCR results in two functionally very different fusion kinases. The two kinases are localized differently. 24, 25 The protein domains contributed by the respective fusion partner result in different mechanisms of activation of the oncogenic kinase, ultimately leading to different degrees of ABL1 kinase activity. This translates into different phosphorylation patterns, the recruitment of different sets of downstream signaling molecules and ultimately in oncogenic transformation of different populations of hematopoietic cells and different disease pathologies. We have compared the catalytic properties of NUP214-ABL1 and BCR-ABL1, their in vitro and cellular sensitivity toward imatinib and dasatinib. Importantly, these two compounds allow to probe for specific conformations of the ABL1 kinase domain and translate into differences in downstream signaling and substrate specificity. Furthermore, we have compared the substrate specificity of NUP214-ABL1 and BCR-ABL1 against 144 immobilized peptides derived from known tyrosine kinase substrates. A cell lysate derived from BCR-ABL1-expressing cells resulted in phosphorylation of a higher number of peptides than a cell lysate of NUP214-ABL1-expressing cells. Moreover, the peptides phosphorylated by both lysates displayed in general a higher V ini for the BCR-ABL1 lysate than for the NUP214-ABL1 lysate. As equal amounts of total protein extract were used in both conditions and the two kinases are expressed to a similar level, these data suggest higher kinase activities in the BCR-ABL1 lysate as compared with the NUP214-ABL1 lysate. This is in agreement with previous experiments in which we showed lower levels of total tyrosine phosphorylation in NUP214-ABL1 cells. 24 Also, we observed weaker autophosphorylation of NUP214-ABL1 as compared with BCR-ABL1 and lower in vitro kinase activity.
We could detect 15 peptides that were phosphorylated by BCR-ABL1, but not NUP214-ABL1, of which a large fraction was also inhibited by imatinib, suggesting that these peptides are specific BCR-ABL1 substrates. However, it is possible that the overall higher kinase activity present in the lysates expressing BCR-ABL1 was sufficient to phosphorylate these 15 peptides. In contrast, only one peptide showed preference for NUP214-ABL1 over BCR-ABL1, and phosphorylation of nine peptides were inhibited by imatinib exclusively in the NUP214-ABL1 lysate. In addition, we could not detect a consensus sequence among the BCR-ABL1-specific substrates, which would represent the preference of a particular sequence present in the peptides that were phosphorylated by BCR-ABL1, but not NUP214-ABL1. Despite the lack of a consensus sequence, there is a clear functional link among the BCR-ABL1-specific substrates including members of the JAK-STAT and mitogenactivated protein kinase pathways that may be activated stronger by BCR-ABL1 than by NUP214-ABL1. In summary, we document a detailed comparative analysis of two ABL1 fusion oncoproteins and reveal unique differences among the two proteins in many properties that will help us to understand the different disease pathologies.
